Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Mont...( -- Posts 33% Sales Growth from Conti...),Health

-- Posts 33% Sales Growth from Continuing Operations in the Fourth Quarter

2007 -- Revises 2008 EPS Guidance Primarily to Reflect the Sale of Medical

Imaging -- Reaffirms Expected Non-GAAP EPS CAGR of at least 15% from 2007 Base

Through 2010, Subject to Certain Assumptions -- Completes Sale of Medical Imaging Business, Reports as Discontinued Operations, with Fourth Quarter EPS of $0.02 and Full-Year EPS of $0.10 -- Posts Fourth Quarter 2007 GAAP Loss Per Share of $0.07 and 2007 Full Year GAAP EPS of $0.99 from Continuing Operations, Impacted by Specified

Items -- Posts Fourth Quarter and Full Year 2007 Non-GAAP EPS of $0.33 and $1.38

from Continuing Operations ($0.35 and $1.48, including Discontinued

Operations), Exceeding Top End of Non-GAAP Guidance Range

NEW YORK, Jan. 31 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today reported financial results for the fourth quarter and twelve months ended December 31, 2007 and revised 2008 earnings guidance primarily to reflect the sale of the Medical Imaging business.

Bristol-Myers Squibb posted fourth quarter 2007 net sales from continuing operations of $5.4 billion, an increase of 33%, including a 5% favorable foreign exchange impact, compared to the same period in 2006. Excluding the estimated adverse impact of generic competition for PLAVIX(R) in 2006, net sales from continuing operations increased 13%. The company reported a fourth quarter 2007 net loss from continuing operations of $133 million, or a loss of $0.07 per diluted share, under U.S. Generally Accepted Accounting Principles (GAAP), compar
'/>"/>